Compare Quest Diagnostics Inc (DGX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs PepsiCo, Inc. — how do they compare? Quest Diagnostics Inc trades at $237.5 (market cap $26.21B), while PepsiCo, Inc. trades at $138.24 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 7.2× Quest Diagnostics Inc's market cap, and PepsiCo, Inc. pays the higher dividend (4.28%). Which is the better fit depends on your goals.
| DGX | PEP | |
|---|---|---|
Market Cap | $26.21B | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $238.50 | $170.44 |
52-Week Low | $173.49 | $134.95 |
Enterprise Value | $31.97B | $231.41B |
Dividend Yield | 1.45% | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
PepsiCo (PEP) trades at $138.11, up 0.3% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78%, and has beaten EPS estimates in recent quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts expect in-line Q1 2026 results.
The stock offers a solid dividend yield and trades below the consensus price target of $158.79, suggesting upside potential. Risks include competitive pressures and sensitivity to consumer spending trends, but strong cash flow and institutional buying support a stable outlook for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
